MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Moleculin Biotech, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.27−0.02 (-5.49%)

Close on Oct 19, 2026

Market cap: $1.51M
P/E (TTM): –
Dividend yield: –

Moleculin Biotech, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM FY 2017 2017-12-31	TTM FY 2016 2016-12-31
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Research & Development	20	18	16	15	16	17	18	20	18	18	19	17	20	20	19	18	16	15	14	13	13	14	13	14	13	11	11	11	9.29	11	9.73	9.09	8.81	4.55	1.50
General & Administrative	9.15	9.13	9.12	8.87	8.90	8.87	8.79	8.88	9.34	9.77	10	11	11	12	12	11	9.63	8.87	8.39	8.06	7.70	6.91	6.79	6.69	6.70	6.53	6.31	6.12	5.69	5.43	5.23	4.96	5.05	4.09	2.38
Operating Expenses	29	27	25	24	25	26	27	29	28	28	30	28	31	32	31	29	26	24	23	21	21	21	20	21	19	18	18	17	15	17	15	14	14	8.65	3.88
Operating Income	-29	-27	-25	-24	-25	-26	-27	-29	-28	-28	-30	-28	-31	-32	-31	-29	-26	-24	-23	-21	-21	-21	-20	-21	-19	-18	-18	-17	-15	-17	-15	-14	-14	-8.65	-3.88
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0.04
Other Non-Operating Income	0.06	0.05	-0.02	0.04	0.03	0.04	0.04	0.05	0.05	0.05	0.05	0.03	0.04	0.04	0.04	0.05	0.04	0.04	0.04	0.03	0.02	0.03	0.03	0.04	0.04	0.02	0.02	-0.01	-0.04	-0.04	-0.04	–	–	0.01	–
Pretax Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-17	–	–	–	-13	–	–	–	–	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.23	-0.23	-0.23	-0.23	0	0	0	0	0	0	0
Net Income	-30	-41	-34	-56	-37	-26	-26	-30	-28	-28	-30	-26	-29	-30	-29	-25	-21	-18	-16	-16	-15	-21	-17	-19	-19	-10	-13	-12	-10	-14	-12	-12	-13	-9.81	-3.93
EPS (Basic)(per share)	–	–	–	-94.14	-124.39	-154.96	-189.14	-298.94	-322.19	-338.44	-376.75	-337.93	-379.93	-394.43	-380.50	-329.55	-273.30	-239.55	-221.25	-278.35	-345.85	-672.10	-660.00	-749.13	-827.88	-512.88	-731.25	-812.89	-790.39	-1,172.89	-1,035.00	-1,147.57	-1,282.57	-1,192.50	-900.00
EPS (Diluted)(per share)	-15.01	-42.29	-54.55	-94.16	-124.42	-154.87	-204.20	-298.73	-322.01	-338.36	-376.47	-337.96	-380.20	-393.63	-380.50	-328.87	-272.32	-239.66	-221.25	-278.35	-345.85	-672.10	-660.00	-749.13	-827.88	-512.88	-731.25	-812.89	-790.39	-1,172.89	-1,035.00	-1,147.57	-1,282.57	-1,192.50	-900.00
Shares Outstanding (Basic, Weighted)(shares)	3.38	2.12	1.18	0.67	0.34	0.21	0.14	0.11	0.09	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.07	0.06	0.05	0.04	0.03	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.00
Shares Outstanding (Diluted, Weighted)(shares)	3.38	2.12	1.18	0.67	0.34	0.21	0.14	0.11	0.09	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.07	0.06	0.05	0.04	0.03	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.00
EBITDA	-29	-27	-25	-24	-25	-26	-27	-29	-28	-28	-30	-28	-31	-32	-31	-29	-26	-24	-23	-21	-21	-21	-20	-21	-19	-18	-17	-17	-15	-17	-15	-14	-14	-8.64	-3.88
Net Interest Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.24	0.18	0.24	0.29	0.31	0.24	0.16	0.07	0.01	0.01	0.02	0.02	0.01	0.01	0.01	0.00	0.00	0.01	0.01	0	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -256.0%

Financial strength

Current ratio: 0.94
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 78.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.13
Dividend yield: –